Sage Therapeutics, Inc.

Symbol: SAGE




Market price today

  • -1.4749

    P/E Ratio

  • 0.0371

    PEG Ratio

  • 742.65M

    MRK Cap

  • 0.00%

    DIV Yield

Sage Therapeutics, Inc. (SAGE) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Barry E. Greene
Full-time employees:487
Address:215 First Street

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.965% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -5.946%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -5.525%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.655% return, is a testament to Sage Therapeutics, Inc.'s adeptness in optimizing resource deployment. Sage Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.609%. Furthermore, the proficiency of Sage Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.767% return on capital employed.

Stock Prices

Sage Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $14.56, while its low point bottomed out at $13.19. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Sage Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing SAGE liquidity ratios reveals its financial health of the firm. The current ratio of 1222.42% gauges short-term asset coverage for liabilities. The quick ratio (1185.22%) assesses immediate liquidity, while the cash ratio (281.53%) indicates cash reserves.

Current Ratio1222.42%
Quick Ratio1185.22%
Cash Ratio281.53%

Profitability Ratios

SAGE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -552.52% underscores its earnings before tax deductions. The effective tax rate stands at -0.62%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 92.92%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -594.59%, we grasp its operational profitability.

Pretax Profit Margin-552.52%
Effective Tax Rate-0.62%
Net Income per EBT100.00%
EBT per EBIT92.92%
EBIT per Revenue-594.59%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 12.22, it details the span from stock purchase to revenue. The 12 days it takes to settle debts showcases its creditor relations. Meanwhile, a 3 cash conversion cycle and 645.43% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding1185
Operating Cycle56.55
Days of Payables Outstanding739
Cash Conversion Cycle-683
Receivables Turnover6.45
Payables Turnover0.49
Inventory Turnover3199000.00
Fixed Asset Turnover20.50
Asset Turnover0.12

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -7.06, and free cash flow per share, -7.07, depict cash generation on a per-share basis. The cash per share value, 11.95, showcases liquidity position. Lastly, the operating cash flow sales ratio, -4.66, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-7.06
Free Cash Flow per Share-7.07
Cash per Share11.95
Operating Cash Flow Sales Ratio-4.66
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-128.47
Short Term Coverage Ratio-128.47
Capital Expenditure Coverage Ratio-1294.92
Dividend Paid and Capex Coverage Ratio-1294.92

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.43%, highlights its total liabilities relative to assets. An interest coverage of -62.65 indicates its ability to manage interest expenses.

Debt Ratio0.43%
Total Debt to Capitalization0.47%
Interest Coverage-62.65
Cash Flow to Debt Ratio-128.47
Company Equity Multiplier1.09

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.44, provides a glimpse into top-line earnings distributed across each share. Net income per share, -9.05, reflects the portion of profit attributed to each share. The book value per share, 13.36, represents the net asset value distributed per share, while the tangible book value per share, 13.36, excludes intangible assets.

Revenue Per Share1.44
Net Income Per Share-9.05
Book Value Per Share13.36
Tangible Book Value Per Share13.36
Shareholders Equity Per Share13.36
Interest Debt Per Share0.09
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 1024.84%, indicates top-line expansion, while the gross profit growth, 1126.48%, reveals profitability trends. EBIT growth, -6.01%, and operating income growth, -6.01%, offer insights into operational profitability progression. The net income growth, -7.59%, showcases bottom-line expansion, and the EPS growth, -6.60%, measures the growth in earnings per share.

Revenue Growth1024.84%
Gross Profit Growth1126.48%
EBIT Growth-6.01%
Operating Income Growth-6.01%
Net Income Growth-7.59%
EPS Growth-6.60%
EPS Diluted Growth-6.60%
Weighted Average Shares Growth0.89%
Weighted Average Shares Diluted Growth0.89%
Operating Cash Flow Growth-17.51%
Free Cash Flow Growth-17.39%
5-Year Revenue Growth per Share-26.18%
3-Year Revenue Growth per Share-93.26%
10-Year Operating CF Growth per Share-765.18%
5-Year Operating CF Growth per Share-59.85%
3-Year Operating CF Growth per Share-170.70%
10-Year Net Income Growth per Share-730.36%
5-Year Net Income Growth per Share-11.93%
3-Year Net Income Growth per Share-177.62%
10-Year Shareholders Equity Growth per Share810.73%
5-Year Shareholders Equity Growth per Share-28.59%
3-Year Shareholders Equity Growth per Share-66.48%
Receivables Growth507.68%
Inventory Growth102.07%
Asset Growth-34.96%
Book Value per Share Growth-36.74%
Debt Growth-57.43%
R&D Expense Growth9.22%
SGA Expenses Growth20.56%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,230,828,676.47, captures the company's total value, considering both debt and equity. Income quality, 1.00, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 3.18, gauges operational efficiency, while the research and development to revenue, 412.05%, highlights investment in innovation.

Enterprise Value1,230,828,676.47
Income Quality1.00
Sales General and Administrative to Revenue3.18
Research and Development to Revenue412.05%
Capex to Operating Cash Flow0.10%
Capex to Revenue-0.64%
Capex to Depreciation-39.70%
Stock-Based Compensation to Revenue84.86%
Graham Number52.16
Return on Tangible Assets-61.37%
Graham Net Net12.26
Working Capital786,603,000
Tangible Asset Value799,530,000
Net Current Asset Value786,603,000
Average Receivables48,334,500
Average Payables14,634,000
Average Inventory-31,577,000
Days Sales Outstanding350
Days Payables Outstanding1744
Days of Inventory On Hand225

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.05, and the price to book ratio, 1.05, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.16, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -1.75, and price to operating cash flows, -1.75, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.05
Price to Book Ratio1.05
Price to Sales Ratio8.16
Price Cash Flow Ratio-1.75
Price Earnings to Growth Ratio0.04
Enterprise Value Multiple-1.93
Price Fair Value1.05
Price to Operating Cash Flow Ratio-1.75
Price to Free Cash Flows Ratio-1.75
Price to Tangible Book Ratio1.62
Enterprise Value to Sales14.24
Enterprise Value Over EBITDA-2.41
EV to Operating Cash Flow-2.28
Earnings Yield-41.76%
Free Cash Flow Yield-41.73%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sage Therapeutics, Inc. (SAGE) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.475 in 2024.

What is the ticker symbol of Sage Therapeutics, Inc. stock?

The ticker symbol of Sage Therapeutics, Inc. stock is SAGE.

What is company IPO date?

IPO date of Sage Therapeutics, Inc. is 2014-07-18.

What is company current share price?

Current share price is 12.340 USD.

What is stock market cap today?

The market cap of stock today is 742645880.000.

What is PEG ratio in 2024?

The current 0.037 is 0.037 in 2024.

What is the number of employees in 2024?

In 2024 the company has 487.